NOVA1

LA JOLLA, Calif.--(BUSINESS WIRE)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the presentation of new pre-clinical data from the company’s SuperNova-1 (SNV1) platform at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022. SNV1 is composed of adipose tissue-derived allogeneic stem cells (AD-MSC) loaded with tumor selective CAL1 oncolytic vaccinia virus that is designed to overcome multiple innate and adaptive immune barriers that restrict traditional oncolytic virotherapies. Early Calidi research has shown the potential ability of the SNV1 platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses’ therapeutic efficacy. The poster presentation details the evaluation of SNV1 in multiple tumor-bearing mouse models, where SNV1 was tested for its ability to resist humoral immune-mediated inactivation in cell culture. Additionally, following either single or three dose regimens, tumor growth inhibition of multiple human xenografts and murine syngeneic models was examined. The study also investiagted the molecular signature associated with the infection of mesenchymal stem cells (MSC) with the oncolytic virus CAL1 by RNA sequencing. “These incremental data validate our belief in the potential of SNV1 and the use of stem cells as a delivery and potentiation platform for oncolytic viruses,” said Antonio F. Santidrian, Ph.D., SVP, Global Head of R&D of Calidi Biotherapeutics. “Through the demonstration of tumor growth inhibition across multiple pre-clinical models as well as the ability to overcome rapid inactivation by the immune system, we believe SNV1 can revolutionize the use of oncolytic virotherapy to treat a broad range of cancers and look forward to advancing this promising asset into the clinic.” Key highlights from the poster presentation are below: The SNV1 stem cell-based platform protects and potentiates oncolytic vaccinia virus by circumventing humoral innate and adaptive immune barriers, resulting in enhanced anticancer effects in tumor-bearing mouse models. SNV1 provided instantly active viral particles for immediate infection in the injected tumors, transforming the tumor environment from “cold” to “hot” locally and systemically, and leading to significant tumor growth inhibitions in multiple human and mouse tumor models. Repeated intratumoral administrations of SNV1 inhibited treated as well as distant untreated tumors. These effects were also associated with a significant increase of tumor infiltrating lymphocytes in both treated and untreated tumors. RNA sequenced genome wide analysis provided insights into the valuable role of stem cells in the immuno therapeutic MOA of SNV1. Full details for the upcoming poster presentation are below: Title: SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy Abstract ID: 1137 Location: Poster Hall C Date: November 10, 2022, 9:00 a.m. - 9:00 p.m. ET Presenters: Duong H. Nguyen, Ph.D., Director of Translational Research and Innovation, and Antonio F. Santidrian, Ph.D., Senior Vice President, Global Head of Research and Development About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in La Jolla, California. For more information, please visit .

LA JOLLA, Calif.--(BUSINESS WIRE)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022. Details of the poster presentation are below: Title: SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy Abstract ID: 1137 Location: Poster Hall C Date: November 10, 2022, 9:00 a.m. - 9:00 p.m. ET Presenters: Duong H. Nguyen, Ph.D., Director of Translational Research and Innovation, and Antonio F. Santidrian, Ph.D., Senior Vice President, Global Head of Research and Development About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in La Jolla, California. For more information, please visit . Forward-Looking Statements This press release may contain forward-looking statements and information relating to, among other things, Calidi Biotherapeutics and its business plan and strategy, and the highly competitive pharmaceutical industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the Company. When used in this press release, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” as well as similar terms, are forward-looking in nature. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Calidi’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Calidi Biotherapeutics does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.